Phase 1b Study of Iberdomide and CC-99282 with R-CHOP for Lymphoma Treatment
A Phase 1b trial is evaluating the safety and efficacy of Iberdomide (CC-220) and CC-99282 combined with R-CHOP for treating lymphoma.
Company
Pharmaceutical intelligence for R-CHOP with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.